Publication Name	World Journal of Immunology
Manuscript ID	41895
Country	Israel

Received	2018-08-30 01:45
Peer-Review Started	2018-08-30 06:17
To Make the First Decision	2018-10-22 00:35
Return for Revision	2018-10-24 09:17
Revised	2018-11-10 18:18
Second Decision	2018-11-29 07:03
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-11-29 23:30
Articles in Press	2018-11-29 23:30
Publication Fee Transferred
Edit the Manuscript by Language Editor	2018-12-08 22:03
Typeset the Manuscript	2018-12-18 02:25
Publish the Manuscript Online	2018-12-21 08:24

ISSN	2219-2824 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Editorial
Article Title	Cancer immunotherapy by targeting immune checkpoint receptors
Manuscript Source	Invited Manuscript
All Author List	Noah Isakov
ORCID	Author(s) ORCID Number Noah Isakov http://orcid.org/0000-0002-1412-0957
Funding Agency and Grant Number
Corresponding Author	Noah Isakov, PhD, Professor, Department of Microbiology, Immunology and Genetics, Ben-Gurion University, POB. 653, Beer Sheva 84105, Israel. noah@bgu.ac.il
Key Words	Immune checkpoint; Immunotherapy; Cancer; Autoimmune diseases; T lymphocytes
Core Tip	The major functions of immune checkpoint receptors are to maintain self-tolerance, prevent immunopathology, and regulate overall immune homeostasis. However, skewed activation of these receptors by cancer cells may lead to suppression of nascent anti-tumor immunity and promote tumor cell growth. Clinical studies demonstrated that blocking of inhibitory immune checkpoint receptors induced durable clinical responses and unprecedented therapeutic benefits in multiple types of malignancies. The present Editorial addresses some of the major immune checkpoint receptor targets in cancer immunotherapy, discusses some of the side effects and limitations in their utilization, and highlights some of the future challenges in the field.
Publish Date	2018-12-21 08:24
Citation	Isakov N. Cancer immunotherapy by targeting immune checkpoint receptors. World J Immunol 2018; 8(1): 1-11
URL	https://www.wjgnet.com/2219-2824/full/v8/i1/1.htm
DOI	https://dx.doi.org/10.5411/wji.v8.i1.1

Full Article (PDF)	WJI-8-1.pdf
Full Article (Word)	WJI-8-1.doc
Manuscript File	41895-Review.docx
Answering Reviewers	41895-Answering reviewers.pdf
Audio Core Tip	41895-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	41895-Conflict-of-interest statement.pdf
Copyright License Agreement	41895-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	41895-Language certificate.pdf
Supplementary Material	41895-Supplementary-Material-revision.docx
Peer-review Report	41895-Peer-review(s).pdf
Scientific Misconduct Check	41895-Scientific misconduct check.pdf
Scientific Editor Work List	41895-Scientific editor work list.pdf